S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:CBLI

Cleveland BioLabs (CBLI) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free CBLI Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.0006
▼
$0.0006
50-Day Range
$2.20
▼
$4.34
52-Week Range
$1.62
▼
$10.97
Volume
55 shs
Average Volume
271,922 shs
Market Capitalization
$9,287.40
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
CBLI stock logo

About Cleveland BioLabs Stock (NASDAQ:CBLI)

Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

CBLI Stock News Headlines

September 2, 2023 | usatoday.com
Eagles' Tyrie Cleveland, Moro Ojomo carted off field after suffering neck injuries
July 28, 2023 | bizjournals.com
Cleveland Construction News
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
June 28, 2023 | health.usnews.com
Best Hospitals in Cleveland, OH
May 22, 2023 | abcnews.go.com
Cleveland EMS worker who went missing for 6 days remains hospitalized after found safe
May 17, 2023 | health.usnews.com
Cleveland Clinic Rehabilitation Hospital
April 19, 2023 | travel.usnews.com
Getting Around Cleveland
March 31, 2023 | thestreet.com
Cleveland BioLabs Stock Gaps Down On Today's Open (CBLI)
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
March 23, 2023 | bizjournals.com
Cleveland Manufacturing News
March 16, 2023 | bizjournals.com
Cleveland Commercial Real Estate News
March 12, 2023 | forbes.com
Cleveland, TN
September 9, 2022 | bizjournals.com
Cleveland News
August 31, 2022 | thestreet.com
5 Stocks Under $5 Making Big Moves
November 15, 2021 | finance.yahoo.com
Statera Biopharma Provides Third Quarter 2021 Financial and Corporate Update
October 26, 2021 | finance.yahoo.com
Cleveland BioLabs Gets Orphan Status for Entolimod in EU
September 24, 2021 | reuters.com
Statera Biopharma Inc
September 8, 2021 | finance.yahoo.com
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
September 7, 2021 | finance.yahoo.com
Statera BioPharma: The Ticker Formerly Known as CBLI
September 2, 2021 | seekingalpha.com
Cytocom to rename as Statera BioPharma
August 31, 2021 | finance.yahoo.com
Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."
August 18, 2021 | seekingalpha.com
Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript
August 16, 2021 | finance.yahoo.com
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast
August 16, 2021 | finance.yahoo.com
Cytocom, Inc. Reports Second Quarter 2021 Financial Results
August 12, 2021 | finance.yahoo.com
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement
August 11, 2021 | finance.yahoo.com
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
August 10, 2021 | finance.yahoo.com
Cytocom, Inc. to Report Second Quarter 2021 Financial Results
See More Headlines
Receive CBLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cleveland BioLabs and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2020
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CBLI
CUSIP
N/A
CIK
1318641
Web
www.cbiolabs.com
Phone
(888) 613-8802
Fax
N/A
Employees
4
Year Founded
2003

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,400,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-32.84%
Return on Assets
-31.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
45.93
Quick Ratio
45.93

Sales & Book Value

Annual Sales
$260,000.00
Price / Sales
0.04
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.87 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
15,479,000
Free Float
N/A
Market Cap
$9,287.40
Optionable
Not Optionable
Beta
0.70

Social Links

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Michael Kevin Handley
    President, Chief Executive Officer & Director
  • Taunia S. Markvicka
    Chief Operating Officer & Director
  • Peter J. Aronstam
    Chief Financial Officer
  • Andrei V. Gudkov
    Global Head-Research & Development
  • Clifford A. Selsky
    Chief Medical Officer

Key Competitors

View All Competitors

CBLI Stock Analysis - Frequently Asked Questions

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) issued its earnings results on Friday, May, 15th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.16 million for the quarter.

What other stocks do shareholders of Cleveland BioLabs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include iBio (IBIO), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Biocept (BIOC) and Co-Diagnostics (CODX).

This page (NASDAQ:CBLI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Fed launches fourth dollar overhaul
Stansberry Research